Welcome!

.NET Authors: Pat Romanski, Steve Mordue, Liz McMillan, Tim Hinds, Kevin Benedict

News Feed Item

Stock Price Movements, New Drug Applications, and Public Offerings - Research Report on Impax, Volcano, Spectrum, XOMA, and Insulet

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 25, 2013 /PRNewswire/ --


Today, Analysts' Corner announced new research reports highlighting Impax Laboratories Inc. (NASDAQ: IPXL), Volcano Corporation (NASDAQ: VOLC), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), XOMA Corporation (NASDAQ: XOMA), and Insulet Corporation (NASDAQ: PODD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Impax Laboratories Inc. Research Report

On December 20, 2013, Impax Laboratories Inc.'s (Impax) stock rose to end the day at $25.02, compared to the previous day's closing price of $23.99, a 4.29% increase. The Company's stock climbed 7.11% over the past three trading days, compared to the Dow Jones Industrial Average which gained 2.18% over the same trading period. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/4c54_IPXL

--

Volcano Corporation Research Report

On December 20, 2013, Volcano Corp.'s (Volcano) stock rose 0.28% to end the day at $21.28. The Company's stock went up by 0.19% over the past three trading days, compared to the Dow Jones Industrial Average which gained 2.18% over the same trading period. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/14bf_VOLC

--

Spectrum Pharmaceuticals, Inc. Research Report

On December 10, 2013, Spectrum Pharmaceuticals, Inc. (Spectrum) announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of Belinostat, a pan-histone deacetylase (HDAC) inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Spectrum stated that application is filed for Accelerated Approval with a request for Priority Review. According to the Company, response from FDA regarding acceptance to file is expected within 60 days from the FDA receipt date. Rajesh C. Shrotriya, MD, Chairman, CEO, and President of Spectrum, said, "Based on the clinical data, belinostat was shown to have an acceptable safety profile and clinical efficacy, with complete responses in heavily pretreated patients. In June, data was presented at an oral session at ASCO which demonstrated the clinical activity of belinostat in treating patients (N=129) with R/R PTCL with an overall response rate of 26% in these heavily pretreated patients that included patients who had received a previous allogeneic or autologous stem cell transplant." The Full Research Report on Spectrum Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/d344_SPPI

--

XOMA Corporation Research Report

On December 18, 2013, XOMA Corp. (XOMA) announced the closing of the offering of 10.9 million shares of its common stock, including 1.4 million shares of common stock which were issued upon the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $5.25 per share. The Company stated that it expects aggregate net proceeds from the offering to be approximately $53.5 million, after deducting the underwriting discount and estimated offering expenses payable by the Company. The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/9a56_XOMA

--

Insulet Corporation Research Report

On December 20, 2013, Insulet Corp.'s (Insulet) stock rose to end the day at $36.72, compared to the previous day's closing price of $36.42, a gain of 0.82%. The Company's stock rose 0.14% over the past three trading days, compared to the Dow Jones Industrial Average which gained 2.18% over the same trading period. The Full Research Report on Insulet Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/75e4_PODD

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.